Ribera Health Group Gives New Opportunities for Cancer Patients

The advancement of medical research opens new doors for cancer patients. Currently, 44% of all clinical trials are conducted in the oncology field, offering alternatives that were previously unavailable to those facing this disease.

The Ribera healthcare group, in collaboration with the Pratia research network, has strengthened its commitment to innovation with a strategic agreement that allows for the expansion of clinical trials in the university hospitals of Vinalopó and Torrejón and in Ribera Povisa hospital. Thanks to this alliance, more and more patients can access innovative treatments before they are widely available.

Studies focused on lung, breast, melanoma, and head and neck cancers are already being conducted in these hospitals, an opportunity that can make a difference in the fight against the disease. “Thanks to modern treatment methods and innovative therapies emerging from clinical trials, the chances of success are greater than ever,” highlight Ribera and Pratia.

Cancer remains one of the leading causes of death in Spain and its incidence continues to rise. According to the Spanish Network of Cancer Registries (REDECAN), 286,664 new cases will be diagnosed in 2024, more than in 2023. However, the evolution of medical research is allowing patients to have more options and better treatment prospects.

Access to Clinical Trials: A Real Opportunity for Patients

The awareness campaign “Together We Can Change the Future” seeks to inform about the importance of clinical trials, access to cutting-edge treatments, and the key role of innovative therapies in the fight against cancer.

“Clinical trials are the only way to prove that a new therapy is more effective than current ones,” explains Dr. Luis Cabezón, head of Oncology at the University Hospital of Torrejón. “If a treatment truly offers benefits, it must be scientifically validated and patients must be informed because they are the first to benefit.”

The specialist emphasizes that, although not all patients can participate in the trials, if a drug proves to be effective, it will be available to many more in the future. Additionally, participation in these studies allows access to innovative therapies that can significantly improve quality of life.

Reference Centers in Oncological Research

The Ribera-Pratia Research Units, located in the hospitals of Torrejón, Vinalopó, and Povisa, have become key centers for the development of new therapies. The collaboration with Pratia, a research network with over 90 centers in Europe, facilitates greater patient access to these treatments in Spain.

“Through this alliance, we can introduce innovative therapies more quickly, expand treatment options, and streamline administrative processes, something essential in a field as dynamic as Oncology,” states Dr. Cabezón. “We want patients to know that clinical trials not only offer new treatment opportunities but also contribute to the advancement of Medicine and the development of future therapies.”

More information about clinical trials at www.pratia.es/oncology/